ClinicalTrials.gg
CompletedNCT06609460NAVIGATEUpdated Jun 18, 2026

Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications

A Phase 2 interventional study of CD388 Injection and Placebo in Influenza, sponsored by Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed at 57 sites in 2 countries. Open to participants aged 18 Years to 63 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 2, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Oct 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5,071
Allocation
Randomized
Ages
18 Years to 63 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 966 studies in Influenza, Human with a site in United States — 60 open to participants now, 85 under way, 7 of them phase 3. Influenza, Human · United States.

Enrollment
80th of 843
5,071 · median 270
Started
2024
with 34 others
Phase 2
161 of 966
7 open now
Registered
903rd of 966
by date

Among the 966 studies in Influenza, Human with a site in United States, this one is the 80th largest by enrollment of the 843 interventional ones that give a count, is one of 35 that started in 2024, is one of 161 in phase 2, and was the 903rd registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

60 of the 966 studies in Influenza, Human with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 18 Years to 63 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 966 studies in Influenza, Human with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness of CD388 in preventing symptomatic laboratory-confirmed influenza infections, as compared to placebo, and to select a dose of CD388 that is effective in preventing the same, when administered as a single dose via 3 subcutaneous (SQ) injections to adult participants in stable health, and to evaluate the safety and tolerability of CD388, as compared to placebo.

Read the detailed description

This is a Phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter dose selection study to evaluate the efficacy, safety, and tolerability of 3 dose levels of CD388 administered as a single dose via 3 SQ injections in adult participants who are not at risk of developing complications from influenza.

03

Conditions studied

  • Influenza

Browse trials for

04

Who can participate

Ages eligible
18 Years to 63 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to provide written and comply with scheduled visits, laboratory tests, and other study procedures.
  2. Males and females 18 to less than 64 years of age.
  3. In the Investigator's clinical judgment, is in stable health at the time of screening and randomization. Participants may not have underlying hematologic, oncologic, renal, , and/or cardiopulmonary illnesses or be considered at risk of developing complications from influenza infection per the CDC guidelines ( [COPD], asthma, immune compromised current cancer [except non-melanomatous skin cancer], or diabetes). Subjects will be included on the basis of medical history and vital signs taken between signing of the informed consent and randomization.
  4. (BMI; calculated as weight in kilograms [kg] divided by height in meters [m] squared) of 18.0 kg/m\^2 to 35.0 kg/m\^2 (inclusive).
  5. Women of (WOCBP) must:

    1. Have a negative pregnancy test (beta-human chorionic gonadotropin [β-hCG]) at screening, AND
    2. Be practicing a highly effective, preferably user-independent method of (failure rate of less than 1 percent per year when used consistently and correctly) from ≥2 weeks prior to randomization and agrees to remain on a highly effective method from Day 1 until 32 weeks after study drug administration, the end of relevant systemic exposure. The Investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the day of administration of study drug.

    A woman is considered of childbearing potential (i.e., fertile) following menarche and until becoming , unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.

  6. Female participants must agree not to donate or freeze eggs (ova, oocytes) for future use for the purposes of assisted reproduction from Day 1 until 32 weeks after study drug administration.
  7. Male participants must wear a condom when engaging in any activity that allows for passage of ejaculate to another person from Day 1 until 32 weeks after study drug administration. Male participants should also be advised of the benefit for a female partner to additionally use a highly effective method of contraception, as condoms could break or leak.

    Note: Contraceptive (birth control) use by participants should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies.

  8. Male participants must agree not to donate sperm from Day 1 until 32 weeks after study drug administration.
  9. Participant agrees not to donate blood from Day 1 until 32 weeks after study drug administration.
  10. Must be able to read, understand, and complete questionnaires in the electronic diary (eDiary), work with smartphones/tablets/computers, and be willing and able to adhere to the prohibitions and restrictions specified in this protocol. If an appropriate language version is not available for the eDiary assessments, the participant should not be enrolled.
  11. Must be willing to provide verifiable identification, has means to be contacted, and is able to contact the Investigator/study site and communicate reliably during participation in the study.

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected allergy or history of anaphylaxis or other serious adverse reactions to zanamivir (following administration of inhaled or intravenous formulations), monoclonal antibodies (including crystallizable fragment [Fc] domains), or any of the components of CD388 or placebo.
  2. Have been diagnosed with influenza (i.e., with medical history [including verbal] of influenza) within the past 6 months prior to randomization.
  3. Has received the current seasonal influenza vaccine prior to screening or is planning to receive the seasonal vaccine during trial participation.
  4. Has an acute illness (including acute respiratory illnesses) or body temperature ≥38.0ºC (≥100.4 degrees Fahrenheit [ºF]) within 7 days prior to study drug administration (Note: Enrollment at a later date, subsequent to resolution [within the screening period] is permitted).
  5. Has had close contact (including household contacts) with someone with laboratory-confirmed influenza or with someone who has been treated with antiviral therapies for influenza within the past 7 days prior to randomization.
  6. Has had close contact (including household contacts) with someone with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (COVID-19) as defined by the US CDC or has had a positive SARS-CoV-2 test within 10 days prior to screening. Please note SARS-CoV-2 testing is NOT required during screening.
  7. Has a serious and/or clinically unstable condition such as psychiatric condition, including recent (within the past year) or active suicidal ideation/behavior, Alzheimer's disease, or any other condition for which, in the opinion of the Investigator, participation would not be in the participant's best interest or that could prevent, confound, or limit the protocol-specified assessments.
  8. Any history of alcohol or drug abuse within the past 2 years or a positive urine drug screen for drugs of abuse (other than tetrahydrocannabinol [THC]) at screening or Day 1. Note: urine drug screen that is positive for a medication prescribed for treatment of ongoing condition is not exclusionary.
  9. Had major surgery (e.g., major cardiopulmonary or abdominal operations) per Investigator judgment within 4 weeks prior to randomization, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to participate in the study.
  10. Screening findings of prolonged corrected for heart rate using Fridericias formula (QTcF) (greater than 450 milliseconds [msec] in males or greater than 470 msec in females), prolonged PR interval (greater than 220 msec), second- or third-degree heart block, or other dysrhythmias.
  11. At the time of screening, any finding that may significantly increase the risk of participation in the study, affect the ability to participate in the study, or impair interpretation of the study data.
  12. Current or planned participation in another clinical study where study intervention is being administered while participating in the current study. Note: Concurrent enrollment is allowed during the follow-up phase of the other clinical study or in case the study intervention in the other clinical study is a marketed product already approved for another indication - exception being if the other study requires study interventions that could affect the safety assessments of the present study (e.g., clinical laboratory tests).
  13. [Exclusion criterion #13 removed during Amendment 1.1-US; placeholder remains to retain numbering of the remaining original exclusion criteria.]
  14. Prior receipt within the past 30 days or 5 half-lives (whichever is longer) or anticipated receipt of any drug, vaccine, or other biologic agent (e.g., monoclonal antibodies) administered for the prevention or treatment of influenza.
  15. Prior receipt of any experimental drug, vaccine, or biologic agent within the past 90 days or 5 half-lives (whichever is longer).
  16. to SQ injections and blood draws (e.g., bleeding disorders).
  17. Has donated ≥450 mL of blood product (1 unit) for any reason within 30 days of screening or plans to donate blood product during the study.
  18. Currently pregnant or breastfeeding, intends to become pregnant or breastfeed, or has a positive pregnancy test during the screening period.
  19. Has direct involvement in the proposed study or other studies under the direction of the Investigator, sub-investigators, or study site; is a family member of an individual with such direct involvement; or is an employee of the Sponsor.
  20. In the opinion of the Investigator, is unlikely to adhere to the requirements of the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
5,071 participants (actual)

Study arms

  • Experimental
    CD388 Low Dose

    Participants are randomized to receive a low dose of CD388 by SQ injection. Participants are randomized at a 1:1:1:1 ratio across the 4 arms.

    Combination Product: CD388 Injection

  • Experimental
    CD388 Medium Dose

    Participants are randomized to receive a medium dose of CD388 by SQ injection. Participants are randomized at a 1:1:1:1 ratio across the 4 arms.

    Combination Product: CD388 Injection

  • Experimental
    CD388 High Dose

    Participants are randomized to receive a high dose of CD388 by SQ injection. Participants are randomized at a 1:1:1:1 ratio across the 4 arms.

    Combination Product: CD388 Injection

  • Placebo comparator
    Placebo

    Participants are randomized to receive placebo by SQ injection. Participants are randomized at a 1:1:1:1 ratio across the 4 arms.

    Combination Product: Placebo

Interventions

  • Combination productCD388 Injection

    CD388 liquid for injection

  • Combination productPlacebo

    Placebo to match

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Protocol-defined Influenza-like Illness (ILI) Occurring ≥7 Days after and up to 24 Weeks after Administration of Study Drug

    Percentage of participants experiencing protocol-defined ILI occurring after administration of CD388, with central laboratory-confirmed reverse-transcriptase polymerase chain reaction positive (RT-PCR+) influenza infection based on the nasopharyngeal (NP) swab result, as compared to placebo.

    Time frame: From Day 8 up to 24 weeks after study drug dosing

  2. Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs) after Administration of Study Drug

    Safety and tolerability of CD388, as compared to placebo, will be evaluated by assessing the number of participants with incidences of TEAEs following the administration of study drug. TEAEs include but are not limited to adverse events (AEs), serious adverse events (SAEs), injection site reactions (ISRs), and any potentially clinically significant changes from baseline seen in vital signs, 12-lead electrocardiograms (ECGs), and clinical laboratory parameters.

    Time frame: From Day 1 through Day 197/End of Study (EOS) after study drug dosing

Secondary outcomes

  1. Percentage of Participants Experiencing Protocol-defined ILI Occurring ≥7 Days after and up to 28 Weeks after Administration of Study Drug

    Percentage of participants experiencing protocol-defined ILI occurring after administration of CD388, with central laboratory-confirmed RT-PCR+ influenza infection based on the NP swab result, as compared to placebo.

    Time frame: From Day 8 up to 28 weeks after study drug dosing

  2. Percentage of Participants Experiencing Protocol-defined ILI (as in Primary Endpoint 1) Except with a Lower Threshold for New Onset of Fever

    Percentage of participants experiencing protocol-defined ILI occurring after administration of CD388, with central laboratory-confirmed RT-PCR+ influenza infection based on the NP swab result, as compared to placebo. New onset of fever is defined as oral temperature ≥37.2 degrees Celsius (°C). Respiratory symptoms are influenza-associated and as described in the protocol. Onset events include those occurring ≥7 days after and up to 24 weeks following study drug administration.

    Time frame: From Day 8 up to 24 weeks after study drug dosing

  3. Percentage of Participants Experiencing Protocol-defined ILI (as in Primary Endpoint 1) Except the Influenza Infection is Based on the Midturbinate (MT) Swab Result

    Percentage of participants experiencing protocol-defined ILI occurring after administration of CD388, with the influenza infection based on the MT swab result, as compared to placebo.

    Time frame: From Day 8 up to 24 weeks after study drug dosing

  4. Percentage of Participants Experiencing an Influenza Infection AND New Onset of Fever AND New Onset of ≥2 Respiratory Symptoms after Administration of Study Drug

    Percentage of participants experiencing a central laboratory-confirmed RT-PCR+ influenza infection based on the NP swab result (first occurrence only) occurring after administration of CD388, as compared to placebo. New onset of fever is defined as oral temperature ≥37.8°C. Respiratory symptoms are influenza-associated and as described in the protocol. Onset events include those occurring ≥7 days after and up to 24 weeks following study drug administration.

    Time frame: From Day 8 up to 24 weeks after study drug dosing

  5. Percentage of Participants Experiencing an Influenza Infection AND New Onset of ≥2 Respiratory Symptoms after Administration of Study Drug

    Percentage of participants experiencing a central laboratory-confirmed RT-PCR+ influenza infection based on the NP swab result (first occurrence only) occurring after administration of CD388, as compared to placebo. Respiratory symptoms are influenza-associated and as described in the protocol. Onset events include those occurring ≥7 days after and up to 24 weeks following study drug administration.

    Time frame: From Day 8 up to 24 weeks after study drug dosing

  6. Percentage of Participants Experiencing an Influenza Infection AND New Onset of ≥1 Respiratory Symptom AND New Onset of ≥1 Systemic Symptom after Administration of Study Drug

    Percentage of participants experiencing a central laboratory-confirmed RT-PCR+ influenza infection based on the NP swab result (first occurrence only) occurring after administration of CD388, as compared to placebo. Respiratory symptoms are influenza-associated and as described in the protocol. Onset events include those occurring ≥7 days after and up to 24 weeks following study drug administration.

    Time frame: From Day 8 up to 24 weeks after study drug dosing

  7. Percentage of Participants Experiencing an Influenza Infection, AND New Onset of ≥2 Respiratory Symptoms, OR ≥1 Respiratory Symptom AND New Onset of ≥1 Systemic Symptom, after Administration of Study Drug

    Percentage of participants experiencing a central laboratory-confirmed RT-PCR+ influenza infection based on the NP swab result (first occurrence only) occurring after administration of CD388, as compared to placebo. Respiratory symptoms are influenza-associated and as described in the protocol. Onset events include those occurring ≥7 days after and up to 24 weeks following study drug administration.

    Time frame: From Day 8 up to 24 weeks after study drug dosing

  8. Percentage of Participants Experiencing an Influenza Infection AND New Onset of Fever, AND New Onset of ≥2 Respiratory Symptoms, OR New Onset of ≥1 Respiratory Symptom Plus New Onset of ≥1 Systemic Symptom, after Administration of Study Drug

    Percentage of participants experiencing a central laboratory-confirmed RT-PCR+ influenza infection (first occurrence only) from either the self-collected MT swab (collected prior to the initiation of any antiviral treatment) or the NP swab collected by a health professional, occurring after administration of CD388, as compared to placebo. New onset of fever is defined as oral temperature ≥38°C. Respiratory symptoms are influenza-associated and as described in the protocol. Onset events include those occurring ≥7 days after and up to 24 weeks following study drug administration.

    Time frame: From Day 8 up to 24 weeks after study drug dosing

  9. Severity (as Composite Symptom Score) of Participant Reported Influenza-like Symptoms as Based on the Self-reported Responses to the Respiratory Infection Intensity and Impact Questionnaire (RiiQ™) Symptom Scale

    Evaluation of the severity (defined as the composite symptom score) of participant reported influenza-like symptoms as based on the self-reported responses to the RiiQ™ Symptom Scale (scored as 0 = none, 1 = mild, 2 = moderate, and 3 = severe) as presented in the participant eDiary. The composite symptom score is defined as the mean of the scores of the non-missing influenza symptoms for each time point. From the time the participant triggers an Acute Respiratory Infection (ARI) Alert in the eDiary until the ARI episode is resolved (defined as 2 consecutive days where all influenza-associated symptoms on the RiiQ™ Symptom Scale have returned to the same severity level as reported at baseline or lower), the participant will complete the RiiQ™ Symptom Scale in the eDiary for a maximum of 29 days, per ARI episode.

    Time frame: On Day 1 (pre-dose baseline); and then once daily from the time the participant triggers an ARI Alert in the eDiary until the ARI episode is resolved for a maximum of 29 days per ARI episode, up to 28 weeks after study drug dosing

  10. Severity (as Area Under the Curve [AUC]) of Participant Reported Influenza-like Symptoms as Based on the Self-reported Responses to the RiiQ™ Symptom Scale

    Evaluation of the severity (presented as AUC) of participant reported influenza-like symptoms as based on the self-reported responses to the RiiQ™ Symptom Scale (scored as 0 = none, 1 = mild, 2 = moderate, and 3 = severe) as presented in the participant eDiary. AUC will be based on scores of the non-missing influenza symptoms for each time point. From the time the participant triggers an Acute Respiratory Infection (ARI) Alert in the eDiary until the ARI episode is resolved (defined as 2 consecutive days where all influenza-associated symptoms on the RiiQ™ Symptom Scale have returned to the same severity level as reported at baseline or lower), the participant will complete the RiiQ™ Symptom Scale in the eDiary for a maximum of 29 days, per ARI episode.

    Time frame: On Day 1 (pre-dose baseline); and then once daily from the time the participant triggers an ARI Alert in the eDiary until the ARI episode is resolved for a maximum of 29 days per ARI episode, up to 28 weeks after study drug dosing

  11. Duration (as Time to Symptom Resolution) of Participant Reported Influenza-like Symptoms as Based on the Self-reported Responses to the RiiQ™ Symptom Scale

    Evaluation of the duration (defined as the time from the first report of influenza-associated symptoms to resolution) of participant reported influenza-like symptoms as based on the self-reported responses to the RiiQ™ Symptom Scale (scored as 0 = none, 1 = mild, 2 = moderate, and 3 = severe) as presented in the participant eDiary. From the time the participant triggers an Acute Respiratory Infection (ARI) Alert in the eDiary until the ARI episode is resolved (defined as 2 consecutive days where all influenza-associated symptoms on the RiiQ™ Symptom Scale have returned to the same severity level as reported at baseline or lower), the participant will complete the RiiQ™ Symptom Scale in the eDiary for a maximum of 29 days, per ARI episode.

    Time frame: On Day 1 (pre-dose baseline); and then once daily from the time the participant triggers an ARI Alert in the eDiary until the ARI episode is resolved for a maximum of 29 days per ARI episode, up to 28 weeks after study drug dosing

  12. Trough Plasma Concentration at 24 Weeks (C[trough24w]) Following Administration of CD388

    Evaluation of the trough plasma concentration at 24 weeks (C\[trough24w\]) after study drug dosing. PK parameters will be assessed in approximately 120 participants at designated sites only.

    Time frame: Based on sampling done at onsite visits on Day 85 (±3 days) and Day 197/EOS (±7 days)

  13. Maximum Plasma Concentration (C[max]) Following Administration of CD388

    Evaluation of the maximum plasma concentration (C\[max\]) after study drug dosing. PK parameters will be assessed in approximately 120 participants at designated sites only.

    Time frame: At onsite visits done on Day 8, Day 29, and Day 85 (each ±3 days) and on Day 197/EOS (±7 days)

  14. Area Under the Plasma Concentration-Time Curve (AUC) Following Administration of CD388

    Evaluation of the area under the plasma concentration-time curve (AUC) after study drug dosing. PK parameters will be assessed in approximately 120 participants at designated sites only.

    Time frame: At onsite visits done on Day 8, Day 29, and Day 85 (each ±3 days) and on Day 197/EOS (±7 days)

07

Study locations

57 sites
  • Pinnacle Research Group, LLC
    Anniston, Alabama 36207, United States
  • Cullman Clinical Trials
    Cullman, Alabama 35055, United States
  • Fiel Family and Sports Medicine/CCT Research
    Tempe, Arizona 85283, United States
  • Del Sol Research Management, LLC
    Tucson, Arizona 85715, United States
  • Baptist Health Center for Clinical Research
    Little Rock, Arkansas 72205, United States
  • Velocity Clinical Research - Huntington Park
    Huntington Park, California 90255, United States
  • Velocity Clinical Research - San Diego
    La Mesa, California 91942, United States
  • Catalina Research Institute, LLC
    Montclair, California 91763, United States
  • Profound Research LLC
    Oceanside, California 92058, United States
  • Acclaim Clinical Research
    San Diego, California 92120, United States
  • Lynn Institute of the Rockies
    Colorado Springs, Colorado 80918, United States
  • Critical Care, Pulmonary & Sleep Associates, PLLP/CCT Research
    Lakewood, Colorado 80228, United States
  • Alliance for Multispecialty Research, LLC
    Fort Myers, Florida 33912, United States
  • Nature Coast Clinical Research
    Inverness, Florida 34452, United States
  • Health Awareness, LLC
    Jupiter, Florida 33458, United States
  • South Florida Research Center, Inc.
    Miami, Florida 33135, United States
  • Clinical Site Partners, LLC dba Flourish Research
    Miami, Florida 33186, United States
  • Floridian Clinical Research
    Miami Lakes, Florida 33016, United States
  • Healthcare Clinical Data, Inc.
    North Miami, Florida 33161, United States
  • DelRicht Research
    Atlanta, Georgia 30329, United States
  • Velocity Clinical Research - Boise
    Meridian, Idaho 83642, United States
  • Optimal Research, LLC
    Peoria, Illinois 61614, United States
  • Velocity Clinical Research - Valparaiso
    Valparaiso, Indiana 46383, United States
  • Velocity Clinical Research - Sioux City
    Sioux City, Iowa 51106, United States
  • Johnson County Clin-Trials
    Lenexa, Kansas 66219, United States
  • DelRicht Research
    Louisville, Kentucky 40205, United States
  • IMA Clinical Research
    Monroe, Louisiana 71201, United States
  • DelRicht Research
    New Orleans, Louisiana 70115, United States
  • DelRicht Research
    Prairieville, Louisiana 70769, United States
  • Profound Research LLC
    Clarkston, Michigan 48346, United States
  • Profound Research LLC
    Farmington Hills, Michigan 48334, United States
  • Profound Research LLC
    Rochester Hills, Michigan 48307, United States
  • DelRicht Research
    Gulfport, Mississippi 39503, United States
  • DelRicht Research
    Springfield, Missouri 65807, United States
  • Sundance Clinical Research, LLC
    St Louis, Missouri 63141, United States
  • Velocity Clinical Research - Norfolk
    Norfolk, Nebraska 68701, United States
  • Velocity Clinical Research - Omaha
    Omaha, Nebraska 68134, United States
  • Velocity Clinical Research - Albuquerque
    Albuquerque, New Mexico 87107, United States
  • IMA Clinical Research
    New York, New York 10036, United States
  • DelRicht Research
    Charlotte, North Carolina 28205, United States
  • Velocity Clinical Research - Cleveland
    Beachwood, Ohio 44122, United States
  • Velocity Clinical Research - Springdale
    Cincinnati, Ohio 45246, United States
  • DelRicht Research
    Tulsa, Oklahoma 74133, United States
  • Velocity Clinical Research - Medford
    Medford, Oregon 97504, United States
  • Velocity Clinical Research - Anderson
    Anderson, South Carolina 29621, United States
  • DelRicht Research
    Charleston, South Carolina 29407, United States
  • Spartanburg Medical Research
    Spartanburg, South Carolina 29303, United States
  • DelRicht Research
    Hendersonville, Tennessee 37075, United States
  • Zenos Clinical Research
    Dallas, Texas 75230, United States
  • Lonestar Clinical Research, LLC
    Dallas, Texas 75243, United States
  • DelRicht Research
    Prosper, Texas 75078, United States
  • Clinical Trials of Texas, LLC dba Flourish Research
    San Antonio, Texas 78229, United States
  • Stephenville Medical & Surgical Clinic
    Stephenville, Texas 76401, United States
  • Alliance for Multispecialty Research, LLC
    Layton, Utah 84041, United States
  • Velocity Clinical Research - Salt Lake City
    West Jordan, Utah 84088, United States
  • Clinical Research Partners, LLC
    Richmond, Virginia 23226, United States
  • hVIVO
    London, E1 1EQ, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Oct 2025, 12 months.

Of 86 industry-sponsored phase 2 interventional studies under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 12 months is above that.

Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2024
First posted
Sep 24, 2024
StartActual
Sep 20, 2024
Primary completionActual
Oct 9, 2025
CompletionActual
Oct 9, 2025
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06609460
Responsible party
Sponsor
First posted
Sep 24, 2024
Start date
Sep 20, 2024
Primary completion
Oct 9, 2025
Completion
Oct 9, 2025
Last update
Jun 18, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion